Dengue exposure accumulated quietly across two decades in coastal Kenya
Children in coastal Kenya carried a sustained burden of dengue virus exposure across a 20-year span, with evidence of infection building year after year and rising sharply during outbreak periods. The pattern matters because dengue has often been discussed as a growing threat in Asia and Latin America, while African transmission has remained under-characterized despite repeated serologic signals. Here, repeated testing of stored serum from an open longitudinal cohort turned that suspicion into a time series: exposure was not sporadic, and it was not confined to a single season or school-age cluster.
Investigators screened 8,025 archived serum samples collected from 1,834 children aged 15 years and younger between 1998 and 2018. Among those samples, 2,287 were seropositive for anti-DENV IgG antibodies, yielding an overall seroprevalence of 28.5% with a 95% confidence interval of 27.5% to 29.5%. In practical terms, roughly one in four samples carried a footprint of prior dengue infection. Because IgG persists after infection, this pattern signals cumulative exposure rather than fleeting viral circulation.
Age-stratified results revealed a steep gradient. Seroprevalence measured 2% in children younger than 1 year and reached 40% among those aged 9 to 10 years. The climb with age is biologically intuitive: more time outdoors, more mosquito bites, and more opportunities for repeated viral contact. In an endemic setting, that trajectory also means that many children acquire dengue immunity early, long before adolescence, while others remain vulnerable in the same households and communities.
One year stood out immediately.
The highest incidence came in 2013, when seroconversion reached 439.7 infections per 1,000 person-years, with a 95% confidence interval of 375.1 to 515.5. That spike coincided with a large outbreak in coastal Kenya. When incidence rises so abruptly, it usually reflects more than background transmission: vector density, rainfall patterns, human movement, and local ecology can all converge to amplify mosquito-borne spread. The data show that the cohort did not simply experience a steady trickle of infections; it also absorbed outbreak-driven surges that sharply accelerated exposure.
Seroconversion signals sustained transmission, not isolated outbreaks
Among 1,343 children who were seronegative at recruitment, the overall incidence rate of dengue infection was 111.5 per 1,000 person-years, with a 95% confidence interval of 102.5 to 121.2. That rate is substantial for a pediatric cohort followed across two decades. It means new infections kept appearing across the study window, even outside the most visible outbreak year. The transmission signal was persistent enough to argue against dengue as an occasional imported event in this setting.
Repeated cross-sectional serology is especially useful in places where acute febrile illness may be caused by several pathogens and dengue testing is not routinely performed. A child who presents with fever in a coastal Kenyan clinic might be evaluated for malaria, bacterial infection, or a nonspecific viral syndrome while dengue remains invisible. Serology fills that gap by mapping cumulative exposure at the population level. It cannot identify the clinical severity of each infection, but it does show where and when children are being infected.
The public health implication is straightforward: dengue is not merely present in coastal Kenya; it has been circulating over time with enough force to leave a measurable immunologic scar on a substantial fraction of children. That should shape surveillance priorities. Clinical teams need better recognition of dengue-compatible illness, and public health programs need stronger tools to track viral circulation during and between outbreak years. Without that, dengue will continue to be underestimated in routine care and in health planning.
The study also raises an important bedside question about burden. Seropositivity tells us that infection occurred, yet it says nothing here about how often those infections led to hospitalization, hemorrhagic disease, dehydration, missed school, or death. The absence of clinical outcome data leaves the true health burden unresolved, even as the exposure burden is now unmistakable. In dengue-endemic regions, that gap can hide a substantial pediatric problem behind a serology curve.
Biologically, the age-related rise in seroprevalence is consistent with repeated vector exposure over childhood. Dengue is transmitted by mosquitoes, and transmission intensity often varies block by block, household by household, and season by season. Children who live in transmission zones accumulate risk quickly, especially where vector control is inconsistent and environmental conditions favor breeding. Outbreak years amplify that baseline risk, producing the sharp incidence peaks seen in this cohort.
The cohort design strengthens the signal because the analysis drew on samples collected over a long interval from the same child population rather than relying on a single cross-section. Still, the study leaves an epidemiologic boundary in place: IgG positivity confirms prior infection, but it does not distinguish serotype, timing of infection within the year, or whether one child experienced multiple infections. Those details matter because dengue immunology and severity can differ across sequential infections, and serologic snapshots alone cannot resolve them.
For clinicians and public health teams in East Africa, the message is practical and immediate. Children in coastal Kenya have faced long-term dengue exposure, and the highest transmission pressures clustered around outbreak periods such as 2013. Better clinical surveillance is needed to determine how much illness this transmission has caused and to guide responses that match the scale of the problem. The data now define the exposure pattern; the next step is measuring the disease burden that followed it.